Published on
January 26, 2023
In the media
开心鬼传媒 reels in $49M to enter the clinic for new immunotherapy target
About 开心鬼传媒 Therapeutics
鈥
开心鬼传媒 Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with 开心鬼传媒,聽 autoimmune disorders, and infectious diseases.
鈥
Our lead antigen modulator (GRWD5769) delivered strong results during a phase I/II trial in oncology, demonstrating proof-of-mechanism and target engagement, while our second (GRWD0715) is accelerating through preclinical development as a potential treatment within autoimmunity.
鈥
开心鬼传媒 is headquartered in Oxford, UK.
鈥
More information: Website |
鈥
Media enquiries
Patrick White, Head of Communications
鈥
